biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
product line
Prestige Antibodies® Powered by Atlas Antibodies
form
buffered aqueous glycerol solution
species reactivity
rat, human, mouse
technique(s)
immunofluorescence: 0.25-2 μg/mL, immunohistochemistry: 1:200-1:500
immunogen sequence
AEEEKLHKPPADSGVDLREVEHFLKAEPEKNGEVVHTPETSV
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SLC16A3(9123)
正在寻找类似产品? 访问 产品对比指南
General description
The gene SLC16A3 (solute carrier family 16 member 3) is mapped to human chromosome 17q25.3. It belongs to the SLC16A family and is a transmembrane protein. SLC16A3 is expressed in testis, small intestine, lung, brain, heart, kidney, and spleen. SLC16A3 is commonly referred to as MCT4 (monocarboxylate transporter 4).
Immunogen
Monocarboxylate transporter 4 recombinant protein epitope signature tag (PrEST)
Application
Anti-SLC16A3 antibody produced in rabbit has been used in: immunohistochemistry, flow cytometry, and immunofluorescence (IF) confocal microscopy to stain human bronchial epithelial cells (HBECs)-short hairpin RNA (shRNA) targeting TP53(shp53 (shp53)-V5-TMPRSS11B cells.
Biochem/physiol Actions
MCTs (monocarboxylate transporters) are important for transporting lactate and other monocarboxylates across the cell membrane. MCT4/SLC16A3 (solute carrier family 16 member 3) is involved in the transport of γ-hydroxybutyric acid and L-lactate. SLC16A3 is up-regulated in triple negative breast cancer. It is responsible for maintenance of pH, lactate secretion and non-oxidative metabolism of glucose in cancer cells. In similar manner, androgens induce glycolytic metabolism and lactate export in prostate cancer cells by regulating SLC16A3 expression.
Features and Benefits
Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.
Every Prestige Antibody is tested in the following ways:
Every Prestige Antibody is tested in the following ways:
- IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
- Protein array of 364 human recombinant protein fragments.
Physical form
Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
Other Notes
Corresponding Antigen APREST75671
Legal Information
Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
法规信息
常规特殊物品
低风险生物材料
此项目有
Chantale Farah et al.
Biomedicines, 10(3) (2022-03-26)
A vast majority of BRAF V600E mutated melanoma patients will develop resistance to combined BRAF/MEK inhibition after initial clinical response. Resistance to targeted therapy is described to be accompanied by specific metabolic changes in melanoma. The aim of this work
J Doyen et al.
Biochemical and biophysical research communications, 451(1), 54-61 (2014-07-25)
(18)Fluor-deoxy-glucose PET-scanning of glycolytic metabolism is being used for staging in many tumors however its impact on prognosis has never been studied in breast cancer. Glycolytic and hypoxic markers: glucose transporter (GLUT1), carbonic anhydrase IX (CAIX), monocarboxylate transporter 1 and
Irina Heid et al.
Cancer & metabolism, 10(1), 24-24 (2022-12-11)
Pancreatic ductal adenocarcinoma (PDAC) lacks effective treatment options beyond chemotherapy. Although molecular subtypes such as classical and QM (quasi-mesenchymal)/basal-like with transcriptome-based distinct signatures have been identified, deduced therapeutic strategies and targets remain elusive. Gene expression data show enrichment of glycolytic
Chantale Farah et al.
International journal of molecular sciences, 24(3) (2023-02-12)
There is currently no consensus to determine which advanced melanoma patients will benefit from immunotherapy, highlighting the critical need to identify early-response biomarkers to immune checkpoint inhibitors. The aim of this work was to evaluate in vivo metabolic spectroscopy using
Ying-Hui Tong et al.
Translational cancer research, 10(3), 1336-1345 (2022-02-05)
The monocarboxylate transporter (MCT) family especially MCT1 and MCT4 have been recognized to play an important role in lactate transport, a key glycolytic product. The expression of MCT1 and MCT4 expression was previously found to be related to poor outcome
商品
Protein-based drug transporters are expressed in Sf9 cells. Understanding the specific mechanisms of tumor cell transporters is an essential aspect of chemotherapeutic drug design.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持